Life Saving Drugs Program

The Life Saving Drugs Program (LSDP) pays for specific essential medicines to treat patients with rare and life-threatening diseases.

Learn about the program

Find out what the Life Saving Drugs Program is, how it works, which medicines are covered and who can access them.

Apply for LSDP-funded treatment

Find the forms treating physicians need to apply for medicines for their patients under the LSDP.

Our expert panel

See the agenda for the next meeting, how to make a submission, and the outcomes of medicine applications and reviews.

Apply to list a new medicine

Medicine sponsors can read our procedure guidance and template for applying to list a medicine on the LSDP.

Browse the Life Saving Drugs Program for

Patients

Find out how to get medicines through the program and what your responsibilities are.

Prescribers

See how to start patients on LSDP medicines, comply with program requirements, and make any required changes over time.

Pharmacists

Find out how to become an LSDP pharmacy, manage LSDP medicines correctly, prevent wastage, and keep us informed.

Medicine sponsors

Read the medicines eligibility criteria and find out how to list a medicine on the LSDP.

Soliris® (eculizumab) available on PBS from 1 March 2022

The program that subsidises Soliris® for patients with a rare condition called paroxysmal nocturnal haemoglobinuria (PNH) is changing. Until now, we have subsidised Soliris® under the Life Saving Drugs Program. From 1 March 2022, this will change to the Pharmaceutical Benefits Scheme (PBS).

Find out more

Latest resources

Latest resources

Life Saving Drugs Program – Pompe disease – Review summary and expert panel recommendations

This Pompe disease review considered alglucosidase alfa. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.

Life Saving Drugs Program – MPS II – Review summary and expert panel recommendations

This MPS II review considered idursulfase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.

Life Saving Drugs Program – Pompe disease – Review summary and expert panel recommendations for consumers

This Pompe disease review considered alglucosidase alfa. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.

Life Saving Drugs Program – MPS II – Review summary and expert panel recommendations for consumers

This MPS II review considered idursulfase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.
Last updated:
Tags: 

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.